Sermorelin vs ipamorelin vs tesamorelin compared: how each peptide works, typical dosing, FDA status, and research on muscle, fat loss, and recovery in adults.
Sermorelin, ipamorelin, and tesamorelin are all peptides that increase growth hormone (GH) signaling, but they act through different receptors and have very different regulatory statuses. Sermorelin and tesamorelin are growth hormone-releasing hormone (GHRH) analogs, while ipamorelin is a selective ghrelin receptor agonist. This comparison covers how each works, typical research dosages, FDA status, and what studies actually show about fat loss, muscle growth, and recovery.
What Each Peptide Is
Sermorelin
Sermorelin is a 29-amino-acid GHRH analog. It binds the GHRH receptor in the pituitary and prompts the body to release its own GH. It was FDA-approved as a diagnostic agent (Geref) to test pituitary function, but it is not approved for anti-aging, weight loss, or muscle growth. In research and clinical settings, sermorelin is usually given as a nighttime subcutaneous injection because GH release is naturally highest during sleep.
Ipamorelin
Ipamorelin is a pentapeptide that acts on the ghrelin/growth hormone secretagogue receptor (GHS-R). It is often described as one of the most selective older GH secretagogues because animal studies suggest it raises GH without large spikes in cortisol or prolactin. Ipamorelin is not FDA-approved for any human use. It is investigated mainly for GH stimulation, recovery, and body composition.
Tesamorelin
Tesamorelin is a stabilized GHRH analog with a longer half-life than sermorelin. It is FDA-approved as Egrifta for HIV-associated lipodystrophy, where it reduces excess visceral abdominal fat. Tesamorelin is not approved for general weight loss or muscle building, and it is typically studied at 1.4 mg to 2 mg per day by subcutaneous injection.
Mechanism of Action: GHRH Analogs vs Ghrelin Agonists
The core difference is the receptor each peptide targets. Sermorelin and tesamorelin mimic GHRH, so they act on pituitary cells that already respond to the body's natural GHRH signal. Ipamorelin mimics ghrelin, a hormone involved in hunger, and works through a separate receptor that also triggers GH release.
- Sermorelin: GHRH receptor agonist; short half-life; pulsatile GH release.
- Ipamorelin: Ghrelin/GHS-R agonist; selective; minimal effect on cortisol and prolactin in animal models.
- Tesamorelin: GHRH receptor agonist; longer half-life; strongest evidence for visceral fat reduction.
Because the mechanisms differ, stacking a GHRH analog with a ghrelin agonist is a common research design. Many protocols combine them to target both pathways, and that logic also appears in three-way discussions such as tesamorelin vs sermorelin vs ipamorelin.
Sermorelin vs Ipamorelin vs Tesamorelin: Side-by-Side Comparison
| Feature | Sermorelin | Ipamorelin | Tesamorelin |
|---|---|---|---|
| Class | GHRH analog (29 amino acids) | Ghrelin/GHS-R agonist (pentapeptide) | Stabilized GHRH analog |
| FDA status | Approved only as a diagnostic agent | Not approved for human use | Approved for HIV-associated lipodystrophy |
| Typical research dose | 100-300 mcg at night | 100-300 mcg, 1-3 times daily | 1.4-2 mg once daily |
| Half-life | Very short (minutes) | Short (about 2 hours) | Longer (about 30-40 minutes) |
Dosing and Administration Differences
Dosing is where searchers often compare sermorelin vs tesamorelin dosage, and the difference is large. Sermorelin is measured in micrograms, while tesamorelin is measured in milligrams.
- Sermorelin: 100-300 mcg subcutaneously at bedtime in most research protocols.
- Ipamorelin: 100-300 mcg per injection, often 1-3 times daily, sometimes combined with a GHRH analog.
- Tesamorelin: 1.4 mg or 2 mg once daily, usually at night; the 2 mg dose is the one used in most clinical trials.
These numbers come from published studies and prescribing information, not from personal-use recommendations. Anyone considering these peptides should talk with a licensed healthcare professional, because self-dosing can cause side effects and legal problems.
Muscle Growth and Body Composition: What the Evidence Shows
No convincing evidence shows that sermorelin, ipamorelin, or tesamorelin builds muscle the way anabolic steroids or resistance training do. Their main studied effect is on growth hormone and, for tesamorelin, on visceral fat.
Tesamorelin has the strongest clinical data. In HIV-associated lipodystrophy trials, it reduced visceral adipose tissue and improved trunk fat without a major change in lean mass. Sermorelin and ipamorelin have much thinner human data, mostly small studies or anecdotal reports. People searching sermorelin vs ipamorelin for muscle growth often find that neither is proven for that goal.
Likewise, sermorelin vs tesamorelin for muscle growth is a comparison without strong human evidence for muscle gain. Tesamorelin may change body composition by reducing visceral fat, but that is not the same as building muscle.
Safety, Side Effects, and Legal Status
Tesamorelin is the only one of the three with FDA approval for a chronic medical condition. Sermorelin is FDA-approved only as a diagnostic agent. Ipamorelin is not FDA-approved for any human use.
- Common side effects: injection-site reactions, joint pain, swelling, and headache.
- Tesamorelin-specific concerns: increased IGF-1, possible fluid retention, and a boxed warning about increased mortality in people with certain conditions.
- Legal status: these peptides are prescription-only or research-only in the US, and buying them online for personal use is not legal or safe.
Growth hormone secretagogues can affect blood sugar, cortisol, and other hormones. Anyone with cancer, diabetes, or pituitary disease should avoid them unless a physician supervises use.
How They Compare With Other Peptides
Sermorelin, ipamorelin, and tesamorelin are often discussed alongside CJC-1295, AOD-9604, and other research peptides. CJC-1295 is a longer-acting GHRH analog, so it is a closer cousin to sermorelin and tesamorelin than to ipamorelin.
A common research idea is a cjc 1295 ipamorelin tesamorelin stack, which combines a GHRH analog with a ghrelin agonist. Other people compare sermorelin vs aod 9604, a fragment of growth hormone studied for fat metabolism. Both topics reflect the same underlying question: which peptide does what, and with what evidence. A related comparison is ipamorelin vs sermorelin, which turns on selectivity versus GHRH activity.
The direct sermorelin vs tesamorelin comparison often comes back to half-life and FDA status. Tesamorelin lasts longer and has an approved medical indication, while sermorelin is shorter-acting and approved only for diagnosis.
Bottom Line
- Sermorelin is a short-acting GHRH analog approved only for diagnostic use.
- Ipamorelin is a selective ghrelin agonist that is not FDA-approved for human use.
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has the best data for visceral fat reduction.
- None of the three is proven to build muscle in healthy adults.
- Talk with a healthcare professional before using any of these peptides.
Frequently Asked Questions
Is sermorelin or ipamorelin better for muscle growth?
Neither sermorelin nor ipamorelin is proven to build muscle in healthy adults. Sermorelin raises growth hormone through the GHRH receptor, while ipamorelin acts on the ghrelin receptor, but muscle growth depends mainly on training, protein intake, and hormones like testosterone. There is no large human trial showing that either peptide adds meaningful lean mass.
What is the main difference between sermorelin and tesamorelin?
Both are GHRH analogs, but tesamorelin has a longer half-life and is FDA-approved for HIV-associated lipodystrophy, while sermorelin is approved only as a diagnostic agent. Tesamorelin is dosed in milligrams (1.4-2 mg daily), whereas sermorelin is dosed in micrograms (100-300 mcg). Tesamorelin also has more clinical evidence for reducing visceral fat.
Are these peptides FDA-approved for weight loss or anti-aging?
No. Tesamorelin is approved only for HIV-associated lipodystrophy, sermorelin only for diagnostic testing of pituitary function, and ipamorelin is not approved for human use at all. The FDA has not approved any of these peptides for weight loss, anti-aging, or athletic performance. Using them for those purposes is off-label or illegal.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.